通过发行123,377股,Hemogenyx筹集了190万英,使总股份增加到640万股. Hemogenyx raises £190K by issuing 123,377 shares, boosting total shares to 6.04M.

Hemogenyx Pharmaceuticals plc于2025年12月18日发行了123,377股新股，通过认股权证行使筹集了190,000英镑，并通过受限股单位归属和变更契约发行股份。 Hemogenyx Pharmaceuticals plc issued 123,377 new shares on 18 December 2025, raising £190,000 from warrant exercises and issuing shares via restricted stock unit vesting and a deed of variation. 这些股份定于2025年12月23日进入伦敦证券交易所,将使发行的股份总数达到6 041 255份。 The shares, set for admission to the London Stock Exchange on 23 December 2025, will bring the total issued shares to 6,041,255. 该公司侧重于血液和自发免疫疾病治疗,将继续推进其临床阶段方案。 The company, focused on blood and autoimmune disease treatments, will continue advancing its clinical-stage programs.